Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Arginine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OTC | P00480 | 1/20 | 0.50 |
| ▸ | GSR | P00390 | 2/20 | 0.47 |
| ▸ | DDAH1 | O94760 | 3/20 | 0.47 |
| ▸ | NOS2 | P35228 | 6/20 | 0.45 |
| ▸ | NOS3 | P29474 | 5/20 | 0.45 |
| ▸ | NOS1 | P29475 | 5/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | APEX1 | P27695 | 1/20 | 0.42 |
| ▸ | GRM8 | O00222 | 1/20 | 0.41 |
| ▸ | GRM6 | O15303 | 1/20 | 0.41 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.41 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.41 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.41 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Arginine SCHEMBL26966738 | 1.00 | OTC (0.50) | OTCGSRDDAH1NOS2NOS3 | |
| Arginine SCHEMBL1533795 | 1.00 | OTC (0.50) | OTCGSRDDAH1NOS2NOS3 | |
| Arginine SCHEMBL536461 | 1.00 | OTC (0.50) | OTCGSRDDAH1NOS2NOS3 | |
| Arginine SCHEMBL877240 | 1.00 | OTC (0.50) | OTCGSRDDAH1NOS2NOS3 | |
| Arginine SCHEMBL8366388 | 1.00 | OTC (0.50) | OTCGSRDDAH1NOS2NOS3 | |
| Arginine SCHEMBL10619515 | 1.00 | OTC (0.50) | OTCGSRDDAH1NOS2NOS3 | |
| Arginine SCHEMBL8895106 | 1.00 | OTC (0.50) | OTCGSRDDAH1NOS2NOS3 | |
| Arginine SCHEMBL1445141 | 1.00 | OTC (0.50) | OTCGSRDDAH1NOS2NOS3 | |
| Arginine SCHEMBL536976 | 1.00 | OTC (0.50) | OTCGSRDDAH1NOS2NOS3 | |
| Arginine SCHEMBL27508634 | 1.00 | OTC (0.50) | OTCGSRDDAH1NOS2NOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 262 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4347822-A2 | HUMAN CHROMOSOME 9 OPEN READING FRAME 72 (C9ORF72) IRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | Alnylam Pharmaceuticals, Inc. (US) | 2024-04-10 | — | — | EP | claimed |
| CN-117625503-A | Method for producing creatine by fermenting sugar raw material by utilizing microorganism | 江南大学 | 2024-03-01 | — | — | CN | claimed |
| CN-117355537-A | Improved biotechnological process for the production of guanidinoacetic acid (GAA) by inactivation of amino acid export proteins | 赢创运营有限公司 | 2024-01-05 | — | — | CN | claimed |
| US-11857534-B2 | Inhibition of dipeptide repeat proteins | ALS THERAPY DEVELOPMENT INSTITUTE (US) | 2024-01-02 | — | — | US | claimed |
| CN-116426497-A | L-arginine-glycine amidino transferase and application thereof in production of guanidinoacetic acid | 江南大学 | 2023-07-14 | — | — | CN | claimed |
| WO-2023101963-A2 | COMPOSITIONS FOR INHIBITING DIPEPTIDE REPEAT PROTEIN-RIBOSOMAL RNA INTERACTION AND USES THEREOF | NORTHWESTERN UNIVERSITY (US) | 2023-06-08 | — | — | WO | claimed |
| CN-115803442-A | Method for preparing guanidinoacetic acid by fermentation | 赢创运营有限公司 | 2023-03-14 | — | — | CN | claimed |
| WO-2022256290-A2 | HUMAN CHROMOSOME 9 OPEN READING FRAME 72 (C9ORF72) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2022-12-08 | — | — | WO | claimed |
| EP-4073251-A1 | HUMAN CHROMOSOME 9 OPEN READING FRAME 72 (C9ORF72) IRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | Alnylam Pharmaceuticals, Inc. (US) | 2022-10-19 | — | — | EP | claimed |
| EP-3990021-A1 | INHIBITION OF DIPEPTIDE REPEAT PROTEINS | ALS Therapy Development Institute (US) | 2022-05-04 | — | — | EP | claimed |
| WO-2008134245-A1 | DEVICES, SYSTEMS, AND METHODS FOR PROMOTION OF INFARCT HEALING AND REINFORCEMENT OF BORDER ZONE | CVDEVICES, LLC (US) | 2008-11-06 | — | — | WO | claimed |
| CN-100424179-C | Process for preparing insulin compounds | NOVO NORDISK AS (DK) | 2008-10-08 | — | — | CN | claimed |
| WO-2007146319-A2 | METHODS AND APPARATUS FOR USING POLYMER-BASED BEADS AND HYDROGELS FOR CARDIAC APPLICATIONS | SYMPHONY MEDICAL, INC. (US) | 2007-12-21 | — | — | WO | claimed |
| EP-0741745-B1 | HEPATITIS B VACCINE | IMPERIAL COLLEGE (GB) | 2005-11-16 | — | — | EP | claimed |
| CN-1589328-A | Process for preparing insulin compounds | NOVO NORDISK AS (DK) | 2005-03-02 | — | — | CN | claimed |
| WO-2004041828-A1 | METHOD OF USING A PORPHYRIN-LIKE MOLECULE CONJUGATED WITH AN ANTI-CANCER DRUG FOR THE TREATMENT OF CANCER | HAN IN SUK (US) | 2004-05-21 | — | — | WO | claimed |
| US-20020155999-A1 | Method of using a porphyrin-like molecule conjugated with an anti-cancer drug for the treatment of cancer | HAN IN SUK (US) | 2002-10-24 | — | — | US | claimed |
| WO-2002017898-A2 | COMPOSITIONS AND METHODS FOR INDUCING VASORELAXATION | SACKS MEIR S (US) | 2002-03-07 | — | — | WO | claimed |
| US-5965696-A | Potassium channel modulators | JOHN WYETH & BROTHER, LTD. (GB) | 1999-10-12 | — | — | US | claimed |
| US-4357343-A | AMINO ACIDS | BAXTER TRAVENOL LABORATORIES, INC. (US) | 1982-11-02 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11857534-B2 | Inhibition of dipeptide repeat proteins | PRMT1, ARGLU1, PRMT3 | OTC 888/4885GSR 2902/4885DDAH1 326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.